Key result
Hypomagnesemia affects up to ~65% of ICU patients, driving refractory electrolyte derangements and arrhythmias.
Answers are grounded in this paper and cite their sources.
Reviews the clinical causes, electrolyte complications, and therapeutic management of hypomagnesemia, highlighting risks of refractory arrhythmias and hypocalcemia.
Hypomagnesemia is a common entity occurring in up to 12% of hospitalized patients (1). The incidence rises to as high as 60 to 65% in patients in intensive care settings in which nutrition, diuretics, hypoalbuminemia, and aminoglycosides may play important roles (2,3,4). Signs and Symptoms of Magnesium Depletion Symptomatic magnesium depletion is often associated with multiple biochemical abnormalities such as hypokalemia, hypocalcemia, and metabolic alkalosis. As a result, it is often difficult to ascribe specific clinical manifestations solely to hypomagnesemia. In 1960, five patients were reported with symptoms considered to be typical of magnesium depletion, including tetany, positive Chvostek and Trousseau signs, and generalized convulsions (5). Somewhat similar findings—generalized weakness, anorexia, hypokalemia, hypocalcemia, and positive Trousseau and Chvostek signs—were noted when magnesium depletion was induced in volunteers (6). Tetany can occur in the absence of hypocalcemia and alkalosis and is presumably due to lowering of the threshold for nerve stimulation (7). Hypokalemia Hypokalemia is a common event in hypomagnesemic patients, occurring in 40 to 60% of cases (8). This relationship is in part due to underlying disorders that cause both magnesium and potassium loss, such as diuretic therapy and diarrhea. There is also evidence of renal potassium wasting in hypomagnesemic patients (6) that is likely due to increased potassium secretion in the loop of Henle and perhaps the cortical collecting tubule. There are several mechanisms that may explain how this might occur. Potassium secretion from the cell into the lumen in the cells of the thick ascending limb and cortical collecting tubule is mediated by ATP-inhibitable luminal potassium channels (9). Hypomagnesemia is associated with a reduction in cell magnesium concentration, which may then lead to a decline in ATP activity, and, due to removal of ATP inhibition, an increase in the number of open potassium channels (9). In addition, decreasing cytosolic magnesium has been shown to directly increase the activity of potassium channels of ascending limb cells (10). Given the very high cell potassium concentration, these changes would promote potassium secretion from the cell into the lumen and enhanced urinary losses. The hypokalemia in this setting is relatively refractory to potassium supplementation and requires correction of the magnesium deficit (11). Bone and Calcium Metabolism The most classical sign of severe hypomagnesemia (<1.0 mEq/L, 0.5 mmol/L, or 1.2 mg/dl) is hypocalcemia. Early in vitro studies showed that a reduction in extracellular magnesium concentration stimulated the secretion of parathyroid hormone (PTH) in the absence of changes in calcium concentration. However, immunoreactive PTH levels in most hypomagnesemic-hypocalcemic patients have been either normal or low (and in some cases undetectable), indicating inappropriately low PTH secretion (12,13). Further evidence for a suppressive effect of hypomagnesemia on PTH secretion is the observation that, in the majority of these patients, parenteral magnesium supplementation leads to a rapid rise in plasma PTH levels (12,13). Several other factors play a role in the mechanism of the hypocalcemia. Parathyroid Hormone Resistance. Failure of hormone secretion cannot explain all of the hypocalcemia, as bone resistance to PTH also plays a role (13). Studies in isolated perfused bone have shown that magnesium depletion interferes with the generation of cAMP in response to perfusion with PTH (14). Why this occurs is not clear. It is possible that severe hypomagnesemia may interfere with G protein activation in response to PTH, thereby minimizing the stimulation of adenylate cyclase. Several findings suggest that PTH resistance may be of greater importance than diminished secretion in most patients. In general, PTH-induced release of calcium from bone is substantially impaired when the plasma magnesium concentration falls below 0.8 mEq/L (1 mg/dl or 0.4 mmol/L); in comparison, diminished PTH secretion appears to require more severe hypomagnesemia. Furthermore, there may be a variable time course for the normalization of the different aspects of calcium and PTH metabolism in hypomagnesemic patients. In some patients, PTH secretion rises significantly earlier than correction of hypocalcemia and restoration of PTH responsiveness (13). This observation is compatible with a primary role for PTH resistance. As noted above, symptomatic hypocalcemia is almost always associated with plasma magnesium levels below 1.0 mEq/L (0.5 mmol/L or 1.2 mg/dl). Mild hypomagnesemia (plasma magnesium concentration between 1.1 and 1.3 mEq/L) can also lower the plasma calcium concentration, but the change is quite small (0.2 mg/dl or 0.05 mmol/L) (15). Vitamin D Deficiency. Low plasma levels of calcitriol (1,25-dihydroxyvitamin D, the most active metabolite of vitamin D) have been noted in hypocalcemic, hypomagnesemic subjects and can contribute to the fall in the plasma calcium concentration. Why this occurs is not clear since, in one study, several days of magnesium replacement normalized plasma calcium and PTH levels but not the concentration of calcitriol (16). Normomagnesemic Magnesium Depletion. A small number of patients have been reported with hypocalcemia responsive to magnesium administration in the absence of detectable hypomagnesemia (13,17). In most of these patients, other tests suggested the presence of magnesium depletion (presumed isolated cellular depletion), such as alcoholism or diarrhea. In a prospective study of 82 patients with alcoholrelated admission diagnoses, for example, 30 had unexplained hypocalcemia (8.0 mg/dl or 2.0 mmol/L), 14 were hypomagnesemic, and 16 had a normal plasma magnesium concentration (17). However, both of the hypocalcemic groups had low mononuclear cell magnesium levels, a finding also seen in normocalcemic patients, and both groups showed normalization of the plasma calcium concentration after the administration of 32 to 64 mEq of elemental magnesium per day for 3 to 5 d. These findings, however, do not conclusively demonstrate that intracellular magnesium depletion is the cause of unexplained hypocalcemia in patients with a normal plasma magnesium concentration. Most patients with chronic alcoholism and diarrhea have tissue magnesium depletion that is independent of the presence or absence of hypocalcemia. Sepsis, hypoalbuminemia, stress, and vitamin D deficiency are among the many factors in these patients that can lower the total and ionized calcium. Furthermore, there were no untreated time controls in this study, and it is possible that resolution of the hypocalcemia may have occurred without magnesium repletion as the clinical status of the patients improved after admission. Nevertheless, it seems reasonable to consider a trial of magnesium replacement in patients with normal renal function who have persistent, unexplained hypocalcemia and are at risk for magnesium deficiency. Heart and Cardiovascular System Magnesium depletion can induce changes in the electrocardiogram. Widening of the QRS complex and peaking of T waves have been described with modest magnesium loss, while more severe magnesium depletion can lead to prolongation of the PR interval, progressive widening of the QRS complex, and diminution of the T wave (18). There are conflicting data as to whether hypomagnesemia is associated with arrhythmia in otherwise healthy subjects. A report on more than 3000 patients from the Framingham Heart Study suggests that the manner in which arrhythmia is defined is an important determinant (19). No association with hypomagnesemia was noted for more than 10 ventricular premature complexes (VPC) per hour or for repetitive VPC. There was, however, an increased risk of complex or frequent (>30/h) PVC with reductions in the plasma magnesium concentration of 0.16 mEq/L (0.2 mg/dl or 0.08 mmol/L) or more. The clinical disturbance of greatest potential importance, however, is the association of mild hypomagnesemia with ventricular arrhythmias in patients with cardiac disease. A number of uncontrolled studies suggest that hypomagnesemia may be an important risk factor for arrhythmias in the setting of an acute ischemic event, congestive heart failure, torsade de pointes, after cardiopulmonary bypass, or in the acutely ill patient in the intensive care unit. The mechanism underlying a possible association between hypomagnesemia and arrhythmias is at present unknown. Arrhythmias could be due to concurrent hypokalemia, hypomagnesemia itself, or both. Magnesium regulates several cardiac ion channels, including the calcium channel and outward potassium currents through the delayed rectifier (20). Lowering the cytosolic magnesium concentration in magnesium depletion will markedly increase these outward currents, shortening the action potential and increasing susceptibility to arrhythmias. Acute Ischemic Heart Disease. Patients with acute myocardial infarction who have mild hypomagnesemia appear to have a two- to threefold increase in the frequency of ventricular arrhythmias in the first 24 h when compared to those with normal plasma magnesium levels (21,22). Uncontrolled studies suggest that the administration of intravenous magnesium at this time can reduce the frequency of potentially fatal ventricular arrhythmias (23,24). A relationship has also been found between the plasma magnesium concentration and ventricular arrhythmias occurring in the second or third week after myocardial infarction. In one study, for example, the mean plasma magnesium concentration was 1.83 mg/dl (0.76 mmol/L) in patients with no abnormal rhythms, 1.68 mg/dl (0.7 mmol/L) in those with multifocal ventricular premature complexes, and 1.55 mg/dl (0.65 mmol/L) in those with unsustained ventricular tachycardia (25). Thirteen patients with complex arrhythmias and hypomagnesemia received intravenous magnesium over 24 h; a normal rhythm was restored in 10. Congestive Heart Failure. An increased incidence of hypomagnesemia has been found repeatedly in patients with congestive heart failure and is presumably due in part to diuretic therapy. A role for magnesium depletion in sudden death has been suggested but is not proven. In a prospective study involving more than 1000 patients with class III or IV heart failure, for example, no correlation was found between hypomagnesemia at the beginning of the study and survival at a median follow-up of 6 mo (26). However, measurements were not made later in the study and all patients were receiving digoxin, diuretics, and an angiotensin-converting enzyme inhibitor, any or all of which may have altered magnesium balance during the course of the study. Torsade De Pointes. The American Heart Association 1992 Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiac Care now include a recommendation that magnesium sulfate be added for the management of torsade de pointes, severe hypomagnesemia, or refractory ventricular fibrillation (27). Torsade de pointes is a unique ventricular tachycardia most commonly precipitated by drugs that prolong the QT interval (e.g., quinidine), electrolyte imbalance (hypokalemia and hypomagnesemia), or a slow heart rate. Treatment is aimed at accelerating the heart rate and/or shortening the QT interval. Intravenous magnesium is now regarded as the treatment of choice even when hypomagnesemia is not present. Cardiopulmonary Bypass. Hypomagnesemia may develop during cardiopulmonary bypass and predispose to arrhythmias. The cause of hypomagnesemia in this setting is unclear. Possible contributing factors include chelation by free fatty acids and/or citrate, and enhanced cellular uptake induced by increasing circulating levels of catecholamines. One prospective study, for example, evaluated 101 patients: 18% had hypomagnesemia before induction compared with 71% following cessation of bypass (28). The hypomagnesemic patients had a significantly higher frequency of atrial dysrhythmias and an increased requirement for prolonged mechanical ventilatory support. A separate study suggested that 2 g of magnesium sulfate given after surgery reduced the level of ventricular ectopy (29). These findings were corroborated in a prospective study of 100 patents who were randomized to either placebo or 2 g of magnesium chloride intravenously after the termination of cardiopulmonary bypass (30). Normomagnesemic patients had significantly fewer postoperative supraventricular and ventricular dysrhythmias, higher indices of cardiac performance, and a less frequent requirement for prolonged mechanical ventilatory support than patients with low plasma magnesium levels. Intensive Care Unit. Hypomagnesemia is extremely common in patients in the intensive care unit and is frequently associated with hypokalemia and hypocalcemia (2,3,31). In one study, for example, hypomagnesemia present on admission to the intensive care unit was associated with a mortality rate approximately twice that of comparably ill normomagnesemic patients (31). It has not been shown, however, that magnesium supplementation would improve the outcome. Coronary Heart Disease. Two large prospective epidemiologic studies have examined the relationship between the serum magnesium concentration and the subsequent development of coronary heart disease (CHD) (32,33). Both suggest that a low serum magnesium is a risk factor for coronary artery disease. One study, for example, examined and followed a cohort of 15,792 subjects aged 45 to 64 yr old over a 4- to 7-yr period as part of the Atherosclerosis Risk in Communities (ARIC) Study (33). The relative risk of CHD across quartiles of serum magnesium in women was 1.0 (in the lowest quartile), 0.92, 0.48, and 0.44. The data in men showed a similar trend but were less striking and did not achieve statistical significance. Both men and women who developed CHD had a lower mean baseline serum magnesium concentration than the disease-free controls. How a low serum magnesium might predispose to CHD is not known. Causes of Hypomagnesemia Approximately one-third of dietary magnesium is absorbed (120 mg) principally in the small bowel. In addition, there is secretion of approximately 40 mg in intestinal secretions and absorption of another 20 mg in the large bowel. Balance is achieved by the urinary excretion of the approximately 100 mg that is absorbed. There is no physiologic hormonal control of plasma magnesium and urinary magnesium excretion. Changes in intake are balanced by changes in urinary magnesium reabsorption, principally in the loop of Henle and the distal tubule in response to changes in plasma magnesium concentration. There are therefore two major mechanisms by which hypomagnesemia can be induced: gastrointestinal or renal losses. Regardless of the cause, hypomagnesemia begins to occur after a relatively small magnesium deficit, because there is little rapid exchange of extracellular magnesium with the much larger bone and cell stores. Gastrointestinal Losses Gastrointestinal secretory losses, which contain some magnesium, are continuous and not regulated. Although the obligatory losses are not large, marked dietary deprivation can lead to progressive magnesium depletion. Magnesium loss will also occur when the intestinal secretions are incompletely reabsorbed as with most disorders of the small bowel, including acute or chronic diarrhea, malabsorption and steatorrhea, and small bowel bypass surgery. A much rarer disorder is an inborn error of metabolism characterized by a selective defect in magnesium absorption (primary intestinal hypomagnesemia). This disease presents in the neonatal period with hypocalcemia responsive to magnesium administration. In some instances, the defect has X-linked recessive inheritance and in others the disorder is autosomally recessive with linkage to chromosome 9q (34). Hypomagnesemia can also be seen in acute pancreatitis. The mechanism is presumably similar to that responsible for at least part of the associated hypocalcemia: of magnesium and calcium in The of hypocalcemia may be by the hypomagnesemia, which can both lower PTH secretion and induce resistance to Losses magnesium losses can be inappropriately increased by of in those in which magnesium that of by a primary defect in renal magnesium and Both loop and can magnesium reabsorption, while the may magnesium and lower magnesium excretion. The of hypomagnesemia induced by the loop and is in part because the associated will to increase and magnesium of the extracellular can magnesium mild hypomagnesemia may as in primary Hypomagnesemia is common in patients to the in one study, for example, the was urinary excretion of magnesium occurred in of the patients with hypomagnesemia. The defect in urinary excretion appears to that is of This effect is modest and other factors contribute to hypomagnesemia in these patients, including dietary acute and diarrhea. Calcium and magnesium to for in the thick ascending limb of the loop of The increased calcium in will more calcium to the loop of the rise in calcium will that of As an example, some patients with primary develop mild hypomagnesemia. drugs can urinary magnesium wasting in this are the and The in loop and distal magnesium may occur before the of and may after the resolution of and acute renal Studies in the for example, have shown a in renal of magnesium and calcium not and 60 of beginning an of The in this setting can be striking and the hypomagnesemia may be to hypocalcemia. an of with less significantly less hypomagnesemia than the of Henle or Magnesium wasting can occur as part of the seen with from acute following renal during a or in patients with Magnesium renal magnesium wasting is an disorder that may present or as a disease In some patients, magnesium wasting is also associated with abnormalities in calcium and potassium have been One is associated with and patients present in or with symptomatic hypocalcemia and are also and to renal and an defect are The with has been to to the and impaired ion secretion due to patients present with hypokalemia presumably due to either and/or of hypomagnesemia on potassium However, some with hypomagnesemia and have normal plasma potassium and a linkage in 14 with normal plasma potassium levels, the for this disorder has been to a interval The second is associated with and hypokalemia and is as It is associated with a defect in the for the The hypokalemia is to the chloride but there is also evidence for of hypomagnesemia The hypomagnesemia has also been to the reduction in chloride which presumably the of The hypomagnesemia in this however, is significantly more marked than that seen with In addition, in a study of the after hypomagnesemia and were present but there were changes in The third presents with isolated magnesium wasting with both an and recessive of inheritance The responsible for one of these has been to a on chromosome in two with an of inheritance of the plasma magnesium concentration is more it is likely that renal magnesium wasting due to and mild renal disease will a more commonly Hypomagnesemia can be seen following at least in part due to chelation by circulating free fatty acids and after therapy of is and the plasma calcium concentration is also ionized hypomagnesemia has been seen during as the of of in the absence of function Hypomagnesemia can also occur as part of the in which there is increased magnesium uptake by bone after or or after correction of chronic Several studies have a higher than frequency of hypomagnesemia in patients with that seems to be with the of It has been not that hypomagnesemia may and may play a role in the of some of the of As a result, the American Association has a that patients with hypomagnesemia magnesium The plasma magnesium concentration is often not as part of the The possible presence of hypomagnesemia be in the following chronic diarrhea, hypocalcemia, refractory hypokalemia, and ventricular during an ischemic the is be for of the plasma magnesium concentration, and intravenous magnesium can be given renal function is relatively hypomagnesemia is the can be from the no cause is the between gastrointestinal and renal losses can be made by the urinary magnesium excretion or the excretion of magnesium on a The can be from the following and to the and plasma of magnesium and The plasma magnesium concentration is by of the circulating magnesium is free to and therefore to be across the The normal renal response to magnesium depletion is to lower magnesium excretion to very low levels. excretion of more than 10 to 30 mg or a excretion of magnesium in a with normal renal function renal magnesium wasting for example, to drugs such as diuretics, or In one study of hypomagnesemic patients, for example, the mean excretion of magnesium in patients with hypomagnesemia of was 0.5 to The in patients with renal magnesium loss was to Normomagnesemic Magnesium Depletion The of normomagnesemic magnesium depletion, as above, be considered as a possible cause of refractory hypokalemia or unexplained hypocalcemia in patients at high risk for magnesium It has been suggested that this can be by low urinary magnesium excretion defined One for example, evaluated patients with chronic diarrhea due to small bowel or disease magnesium excretion was mg in these patients compared to mg in control subjects. The plasma magnesium concentration was lower in the patients with small bowel disease 2.0 mg/dl 0.8 of had a normal to underlying magnesium depletion is to demonstrate reduced excretion over 24 of an magnesium of given over the However, the of this is Patients with diarrhea, or diuretic have a positive of whether have or symptoms to magnesium depletion It seems to magnesium to these patients have unexplained hypocalcemia and/or Treatment The of magnesium repletion with the of the clinical As an example, the patient with or the patient of ventricular arrhythmias mEq of intravenous magnesium given over to 24 This can be as to the plasma magnesium concentration 1.0 mg/dl mmol/L or 0.8 In the normomagnesemic patient with hypocalcemia, it has been suggested to this for 3 to 5 (17). It be that the plasma magnesium concentration is the major of magnesium in the loop of the major of active magnesium an in the plasma magnesium concentration will the to magnesium and up to of the magnesium will be in the Furthermore, magnesium uptake by the cells is slow and repletion requires correction of the hypomagnesemia. these replacement be given in the with a There are several such including magnesium chloride and magnesium These 5 to mEq to or 60 to mg) of magnesium per to be in for severe magnesium depletion. Two to may be for disease. The underlying disease also be Patients with hypomagnesemia induced by a or loop diuretic who cannot diuretic therapy may from the of a diuretic such as These drugs may magnesium excretion by increasing in the cortical collecting tubule. also may be in associated with urinary magnesium wasting such as or or In these magnesium repletion may be relatively the plasma magnesium concentration as above, lead to increased magnesium excretion.
No takes yet. Share an insight, caveat, or question.
Zalman S. Agus (1999) conducted a review in Hypomagnesemia. Magnesium repletion was evaluated. Hypomagnesemia occurs in up to 12% of hospitalized patients, frequently causing refractory hypokalemia, hypocalcemia, and cardiac arrhythmias requiring magnesium repletion.
Synapse has enriched 10 related papers. Consider them for comparative context: